metabolic dysfunction-associated fatty liver disease
Conditions
Interventions
Observation group:none
Sponsors
Shenzhen Hospital of Southern Medical Unversity
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Control group: Does not meet the MAFLD diagnostic criteria (abdominal ultrasound or FibroScan CAP value =1.0 mmol/L for men / >=1.3 mmol/L for women); 2. MAFLD group with normal transaminases: Meets the MAFLD diagnostic criteria (imaging evidence of liver fat, overweight/metabolic syndrome); liver function is normal (ALT = 2 times the upper limit of normal (ALT > 80 U/L);
Exclusion criteria
Exclusion criteria: 1.Control group: Alcohol abuse (males >20 g/day, females >10 g/day) or recent history of alcohol consumption; history of chronic liver disease (viral hepatitis, autoimmune liver disease, drug-induced liver injury, intrahepatic bile duct stones, etc.; hepatic cysts and hemangiomas are not excluded); concurrent intestinal diseases (inflammatory bowel disease, intestinal tumors, acute infection); immune diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.); malignant tumors or use of immunosuppressants/antibiotics (within the last 3 months); 2.MAFLD Group with Normal Transaminases:Alcohol abuse (males >20 g/day, females >10 g/day) or recent history of alcohol consumption; history of chronic liver disease (viral hepatitis, autoimmune liver disease, drug-induced liver injury, intrahepatic bile duct stones, etc.; hepatic cysts and hemangiomas are not excluded); concurrent intestinal diseases (inflammatory bowel disease, intestinal tumors, acute infection); immune diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.); malignant tumors or use of immunosuppressants/antibiotics (within the last 3 months); 3.MAFLD Group with Abnormal Transaminases:Alcohol abuse (males >20 g/day, females >10 g/day) or recent history of alcohol consumption; history of chronic liver disease (viral hepatitis, autoimmune liver disease, drug-induced liver injury, intrahepatic bile duct stones, etc.; hepatic cysts and hemangiomas are not excluded); concurrent intestinal diseases (inflammatory bowel disease, intestinal tumors, acute infection); immune diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.); malignant tumors or use of immunosuppressants/antibiotics (within the last 3 months);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Abdominal ultrasonography;liver stiffness measurement (LSM);Serum biochemistry; | — |
Countries
China
Contacts
Public ContactWang Anjiang
Shenzhen Hospital of Southern Medical Unversity
Outcome results
None listed